Activated Prothrombin Complex Concentrate to Treat Bleeding Events in Acquired Hemophilia A: Bahas Study.

Activated prothrombin complex concentrate (aPCC) is a bypassing agent indicated to treat bleeds in patients with acquired hemophilia A (AHA). Nevertheless, its efficacy and safety in the real‐world setting have not often been addressed.

[1]  M. Lim,et al.  Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  J. Rodriguez-Garcia,et al.  Management of acquired hemophilia A: results from the Spanish Registry. , 2021, Blood advances.

[3]  J. Eikenboom,et al.  Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study , 2020, American journal of hematology.

[4]  W. Sperr,et al.  Emicizumab for the treatment of acquired hemophilia A. , 2020, Blood.

[5]  P. Giangrande,et al.  International recommendations on the diagnosis and treatment of acquired hemophilia A , 2020, Haematologica.

[6]  Acquired , 2020, Definitions.

[7]  F. Xue,et al.  Outcome of CARE: a 6‐year national registry of acquired haemophilia A in China , 2019, British journal of haematology.

[8]  P. Giangrande,et al.  Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  C. Santoro,et al.  Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry , 2018, Journal of Thrombosis and Thrombolysis.

[10]  C. Leissinger,et al.  Acquired hemophilia A: Updated review of evidence and treatment guidance , 2017, American journal of hematology.

[11]  M. Franchini,et al.  Acquired hemophilia A: a review of recent data and new therapeutic options , 2017, Hematology.

[12]  V. Jiménez‐Yuste,et al.  Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors , 2016, European journal of haematology.

[13]  P. Prandoni,et al.  Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study. , 2015, Thrombosis research.

[14]  I. Durieu,et al.  FEIBA in the treatment of acquired haemophilia A: Results from the prospective multicentre French ‘FEIBA dans l'hémophilie A acquise’ (FEIBHAC) registry , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  R. Greil,et al.  Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. , 2015, Blood.

[16]  J. Goudemand,et al.  Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  V. Arocas Casañ,et al.  Acquired haemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribarivin: role of rituximab. , 2013, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

[18]  H. Schwarz,et al.  Factor Eight Inhibitor Bypassing Activity , 2012 .

[19]  F. Pellegrini,et al.  Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. , 2012, Blood.

[20]  J. Esser,et al.  Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) , 2012, Journal of thrombosis and haemostasis : JTH.

[21]  J. Goyal,et al.  Acquired haemophilia in a patient treated with interferon‐α for hepatitis C infection , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  D. Georgescu,et al.  Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin. , 2012, Journal of gastrointestinal and liver diseases : JGLD.

[23]  M. Bokarewa,et al.  Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. , 2009, Clinical and experimental rheumatology.

[24]  T. Baglin,et al.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. , 2007, Blood.

[25]  D. Laber,et al.  Interferon-α-Associated Acquired Factor VIII Inhibitor. , 2005 .

[26]  L. Aledort.  Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity , 2004, Journal of thrombosis and haemostasis : JTH.

[27]  S. Sallah.  Treatment of acquired haemophilia with factor eight inhibitor bypassing activity , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  H. Ehrlich,et al.  Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.